Related Experiment Video

Updated: Aug 23, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma

Lucia Loni1, Filippo De Braud, Pier Luigi Zinzani

  • 1Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, via Roma 55, University of Pisa, Pisa 56126 Italy.

Leukemia & Lymphoma
|June 19, 2004
PubMed

Insights

Understanding genetic and protein expression in tumor cells is key to personalized cancer treatment. Pharmacogenetics and pharmacoproteomics will help tailor chemotherapy for non-Hodgkin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor response variability to chemotherapy necessitates personalized treatment strategies.
  • Molecular profiling of tumor cells reveals genetic backgrounds influencing drug sensitivity.
  • Understanding molecular alterations is crucial for developing targeted anticancer therapies.

Purpose of the Study:

  • To investigate how molecular alterations in tumor cells affect sensitivity to chemotherapy.
  • To highlight the role of pharmacogenetics and pharmacoproteomics in optimizing cancer treatment.
  • To explore the potential for tailoring chemotherapeutic regimens for individual patients with non-Hodgkin's lymphoma.

Main Methods:

  • Profiling tumor cells for genetic background and molecular alterations.
  • Investigating gene and protein expression in relation to drug response.
  • Utilizing advances in molecular pathway knowledge for therapeutic selection.

Main Results:

  • Personalized anticancer treatments based on individual molecular profiles are emerging.
  • Pharmacogenetics and pharmacoproteomics are identified as key disciplines for this advancement.
  • Understanding molecular pathway influence on drug sensitivity is essential for treatment optimization.

Conclusions:

  • Tailoring chemotherapy based on molecular alterations in tumor cells represents the future of cancer treatment.
  • Pharmacogenetics and pharmacoproteomics are instrumental in developing optimal chemotherapeutic regimens.
  • Further research in these novel disciplines will improve outcomes for non-Hodgkin's lymphoma patients.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...